Le Lézard
Classified in: Health
Subjects: CHI, TDS, FVT

Upsher-Smith To Attend The 48th Annual Meeting Of The Child Neurology Society


MAPLE GROVE, Minn., Oct. 22, 2019 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it will be attending the 48th Annual Meeting of the Child Neurology Society (CNS) October 23-26, 2019 in Charlotte, NC. Meeting attendees are encouraged to visit booth #414 to learn more about Vigadrone® (vigabatrin) for Oral Solution, 500 mg a fully substitutable, AA-rated generic version of Sabril® (vigabatrin) powder for oral solution*. Representatives will also be on hand to discuss Upsher-Smith's Access Pathways® Program, a program designed to reduce the barriers associated with prescribing vigabatrin by providing brand-quality support to physicians, patients, and caregivers.

Upsher-Smith Laboratories, LLC. (PRNewsfoto/Upsher-Smith Laboratories, LLC)

Vigadrone® is indicated for the treatment of:

Please see Important Safety Information, including Boxed Warning for Risk of Permanent Vision Loss at the end of this communication.

"At this year's Child Neurology Society meeting, we look forward to discussing with healthcare professionals how Upsher-Smith's Access Pathways® Program can help overcome the obstacles of prescribing vigabatrin," said Rusty Field, President and CEO of Upsher-Smith. "Since treating infantile spams requires early intervention, our priority is to ensure that physicians are able to start their patients on Vigadrone® as quickly as possible."

Access Pathways® is fully committed to providing the support patients and caregivers need, regardless of when they need it. The program includes:

To learn more about Access Pathways®, visit vigadrone.com. Access Pathways® Program Support can be reached at 1-866-923-1954 Monday-Friday from 8:00 a.m. ? 8:00 p.m. EST or at 1-866-923-1954 on weekends and after hours.

Vigabatrin REMS Program
The U.S. FDA has approved a single shared system Risk Evaluation and Mitigation Strategy (REMS) for all vigabatrin products called the Vigabatrin REMS Program. It is required by the FDA to ensure informed risk-benefit decisions before initiating treatment and to ensure appropriate use of vigabatrin while patients are treated.

Healthcare providers must be certified in the Vigabatrin REMS Program to prescribe Vigadrone® and patients must be enrolled in the Vigabatrin REMS Program to receive Vigadrone®. All certified prescribers and enrolled patients in the SABRIL® REMS Program have been transitioned to the Vigabatrin REMS Program and do not need to recertify or re-enroll. 

WHAT IMPORTANT SAFETY INFORMATION SHOULD I KNOW ABOUT VIGADRONE?

WARNING: PERMANENT VISION LOSS
See Medication Guide and full Prescribing Information for complete information.

All people who take VIGADRONE:
   * You are at risk for permanent vision loss with any amount of VIGADRONE. 
   * Your risk of vision loss may be higher the more VIGADRONE you take daily and the longer you take it. 
   * It is not possible for your healthcare provider to know when vision loss will happen. It could  
     happen soon after starting VIGADRONE or any time during treatment. It may even happen after treatment 
     has stopped.

VIGADRONE can cause serious side effects such as low red blood cell counts (anemia), sleepiness and tiredness, nerve problems, weight gain, and swelling. Because VIGADRONE causes sleepiness and tiredness, do not drive, operate machinery, or perform any hazardous task, unless it is decided that these things can be done safely. VIGADRONE may make certain types of seizures worse. Tell your healthcare provider right away if seizures get worse.

Before starting VIGADRONE, tell your doctor about all of your (or your child's) medical conditions, including mental illnesses, and all the medicines you (or your child) take.

If you are breastfeeding or plan to breastfeed, VIGADRONE can pass into breast milk and may harm your baby. 

If you are pregnant or plan to become pregnant, it is not known if VIGADRONE will harm your unborn baby. You and your healthcare provider will have to decide if you should take VIGADRONE while you are pregnant.

The most common side effects of VIGADRONE in adults include: problems walking or feeling uncoordinated, feeling dizzy, shaking (tremor), joint pain, memory problems and not thinking clearly, and eye problems like blurry vision, double vision, and eye movements that cannot be controlled.

The most common side effects of VIGADRONE in children 10 to 16 years of age include weight gain, upper respiratory tract infection, tiredness, and aggression. Also expect side effects like those seen in adults.

The most common side effects of VIGADRONE in babies include: sleepiness?some babies may have a harder time suckling and feeding or may be irritable, swelling in the bronchial tubes (bronchitis), ear infection, and irritability.

Tell your healthcare provider if you or your child have any side effect that bothers you or that does not go away. 

This is the most important information to know about VIGADRONE, but not all of the possible side effects of VIGADRONE. For more information, ask your healthcare provider or pharmacist, or please visit vigadrone.com/PI for VIGADRONE Medication Guidefull Prescribing Information including Boxed Warning for risk of permanent vision loss, and Instructions for Use. You can also visit upsher-smith.com or call 1-888-650-3789.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-332-1088.

About Upsher-Smith
Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. Since 1919, it has brought generics and brands to a wide array of customers backed by an attentive level of service, strong industry relationships, and dedication to uninterrupted supply.        

As Upsher-Smith celebrates its 100-year anniversary, the company enters a new ambitious era that has been accelerated by its 2017 acquisition by Sawai Pharmaceutical Co., Ltd. Upsher-Smith and Sawai plan to leverage each other for growth worldwide and embark on an exciting new chapter as they seek to deliver the best value for their stakeholders, and most importantly, Do More Goodtm for the patients they serve. For more information, visit www.upsher-smith.com.

*Sabril is a registered trademark of Lundbeck.
?Prior authorization support can be provided only for indicated disease states.
**Medicare, Medicaid and other state and federal health care program patients are not eligible.

Vigadrone, Access Pathways and Do More Good are trademarks of Upsher-Smith Laboratories, LLC.

Upsher-Smith Celebrates a Century of Serving Patients (PRNewsfoto/Upsher-Smith Laboratories, LLC)

SOURCE Upsher-Smith Laboratories, LLC


These press releases may also interest you

at 01:35
Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext : NANO ? ISIN : FR0011341205 ? the ??Company'') today announced promising results from its pre-clinical collaboration1 with The University of Texas MD Anderson Cancer Center. The research, which...

at 01:05
Promethera® Biosciences SA ("Promethera®") and MEDIPAL HOLDINGS CORPORATION ("MEDIPAL") today announced that they have entered into a business alliance agreement. In conjunction with today's alliance, MEDIPAL has decided to increase its shareholdings...

at 00:00
REPROCELL Inc. a stem cell and drug discovery company has announced today that they have been selected by Lantern Pharma to provided preclinical screening and drug sensitivity for its portfolio of oncology drugs. The collaboration is designed to...

at 00:00
Mercy Medical Center has been awarded an 'A' in the fall 2019 Leapfrog Hospital Safety Grade, a national distinction recognizing Mercy's achievements protecting patients from harm and providing safer health care. Mercy was one of 10 hospitals in...

11 nov 2019
NEC Corporation (NEC; TOKYO: 6701), a leader in IT and network technologies, and VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that the companies have signed a strategic clinical trial...

11 nov 2019
Tactilis announced today that referencing last year's partnership publication, the Government of Madeira and technology group Tactilis, now based on complete systems developed, will proceed with pilots of a new digital identity platform that enables...



News published on 22 october 2019 at 12:18 and distributed by: